Founded in 1969, AAKP is the largest and oldest independent kidney patient organization in America. Governed by a patient-majority Board of Directors, AAKP conducts national education programs designed to better inform kidney patients, care-givers and policy-makers about the true impacts of kidney disease, prevention efforts and treatment methods. AAKP executes a national advocacy strategy in conjunction with allied kidney organizations designed to insert the patient voice into proposed policies, research efforts and care deliberations before the Executive Branch and the U.S. Congress. Visit our website at www.aakp.org.
Follow AAKP on social media at: https://www.facebook.com/kidneypatient and @kidneypatients
As one of the few national pharmacies able to dispense Jynarque (tolvaptan), Avella is proud to serve the PKD community. To learn more, visit www.avella.com/Jynarque.
COTA is the largest organization dedicated to helping transplant families raise funds for transplant-related expenses, and is honored to be the premier organization providing fundraising assistance to families. Since 1986 more than $100 million has been raised across the country for thousands of individuals needing a life-saving organ, bone marrow or stem cell transplant. COTA can work with PKD patients of any age.
Clinical Research Consultants is conducting clinical trials in patients with rare kidney diseases such as PKD, IgA Nephropathy, FSGS, and Alport Syndrome. Our mission is to provide the highest quality patient care while exceeding Good Clinical Practice guidelines and following Federal Regulations in all aspects of Phase II, II and IV trials.
The Jared Grantham Kidney Institute's mission is to support basic, clinical and translational research leading to major advances in the prevention and treatment of kidney diseases. As one of the top kidney research centers in the country, our scientists and physicians work together to develop better treatments for patients with kidney disease.
Kadmon is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. The company’s pipeline is focused on inflammatory, fibrotic and genetic diseases. Kadmonis conducting ongoing clinical trials of tesevatinib, its oral EGFR inhibitor, in adults with autosomal dominant polycystic kidney disease (ADPKD) and in pediatric patients with autosomal recessive polycystic kidney disease (ARPKD). To learn more, visit www.kadmon.com or contact firstname.lastname@example.org.
Nebraska Medicine is the most esteemed academic health system in Omaha and the surrounding areas. Nebraska Medicine and its research and education partner, the University of Nebraska Medical Center (UNMC), share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.
PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, is quad-accredited and a back-to-back Zitter Health Insights Patient Choice Award winner headquartered in Pittsburgh, Pennsylvania. PANTHERx® Specialty's mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. PANTHERx® works daily to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care®, by developing focused solutions, bold innovations, and novel clinical services associated with life-transforming therapies.
We have been involved in PKD research for the past 35 years conducting clinical and laboratory studies in adults and children. This research has been funded since 1985 by the National Institutes of Health, Department of Defense, PKD and Zell Family Foundations. Our early research focused on defining the natural history, genetic and cellular basis of PKD. More recently our research has investigated ways to intervene in the progression of PKD and identify factors affecting disease severity (HALT, Adult/Children's High Blood Pressure studies, Children's and adult Statin studies, Genetic Modifier, Tolvaptan , Spironolactone, Metformin, and Curcumin Studies).
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
An organization who wishes to reach the PKD community without becoming a sponsor may still participate as an exhibitor!
Become an exhibitor